

The Centers for Disease Control and Prevention (CDC) has released the 2016 Sexually Transmitted Diseases Gap Assessment Toolkit. The tool can be accessed at <a href="https://www.cdc.gov/std/program/gap/default.htm">https://www.cdc.gov/std/program/gap/default.htm</a>.

The Sexually Transmitted Diseases (STD) Preventive Services Gap Assessment Toolkit serves as a general resource for health departments, community-based organizations (CBOs) and others that provide STD-related services. The toolkit is designed for use in the execution of a gap assessment, one of four assessment activities identified in the Division of STD Prevention's 2015 – 2019 program funding announcement (STD AAPPS). The toolkit, however, is not limited to that usage.

One purpose of an STD prevention services gap assessment is to uncover the scope and distribution of STD prevention and care services in a given area, for a defined population, or some combination of both. This activity includes discovering which STD prevention services are offered in conjunction with each other in which settings (e.g., STD testing, diagnosis and onsite treatment). When people seek STD evaluation or care at facilities without sufficient capacity to manage such patients, the type and quality of STD care they receive can be affected. This toolkit provides STD program staff and others a resource for assessing how levels of care are distributed across a given area.

Moreover, individuals who benefit from STD prevention services frequently also benefit from other health and social services. Some STD prevention programs and other health care facilities offer an array of preventive services (e.g., insurance enrollment) or refer patients to other needed services (e.g., homeless shelters or substance abuse treatment centers). Thus a gap assessment can also be used for a **second purpose**, to discover how STD prevention services are interlinked with other health care, health promotion and social services in a given area.

Conducting a gap assessment therefore enables an STD program to identify, document and learn about the array of STD clinical and other preventive services across a defined geographic area or for a defined population. A gap assessment also enables an STD program to learn more about the associations and partnerships among these organizations. Such information may be used to inform program activities to improve STD prevention.

#### The Toolkit

The information presented in the toolkit is based on formative work conducted by CDC collaborating with STD programs in the field. The toolkit provides assistance in planning, conducting and analyzing data from a gap assessment, including selecting the scope of an assessment, identification of facilities to assess, and how to manage data collection. The guidance is intended to be flexible with respect to populations, services and catchment areas. Although STD programs constitute the priJuney audience for this toolkit, the material may be used to guide gap assessments by other organizations and in other content areas.

The Alabama STD Report: Vol. 2016, No. 3 represents preliminary statistics and trends of sexually transmitted diseases in Alabama from January 1 through June 31, 2016. All reports are presented by date of diagnosis. This report is intended as a reference document for local health departments, program managers, health care providers. community based organization, state legislators, researchers and others who are concerned with the public health implications of these diseases. The information in this quarterly report is meant to be brief and provide limited data on these diseases throughout the year. More detailed and complete information will continue to be available in annual publications. This report and our annual publications will be available on our website (http://adph.org/std). National data about these diseases is available on the Centers for Disease Control and Prevention's website (http://cdc.gov).

#### CHLAMYDIA SURVEILLANCE DATA

Chlamydia case reports represent persons who have a positive laboratory test for chlamydia. It is important to note that chlamydial infection is often asymptomatic in females and males. Most cases are detected through screening. The disease can cause serious complications in females including pelvic inflammatory disease. Asymptomatic infection is common among both men and women. Annual screening of all sexually active women ≤ 25 years of age is recommended. as is screening of older women with risk factors (e.g., those who have a new sex partner or multiple sex partners). Screening programs have been demonstrated to reduce both the prevalence of C. trachomatis infection and rates of pelvic inflammatory disease (PID) in women. The screening of sexually active young men should be considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, correctional facilities and STD clinics).

#### **GONORRHEA SURVEILLANCE DATA**

Gonorrhea case reports represent persons who have a positive laboratory test for gonorrhea. The majority of urethral infections

caused by N. gonorrhoeae among men produce symptoms that cause them to seek curative treatment sooner to prevent serious sequelae, but treatment might not be soon enough to prevent transmission to others. Among women, gonoccocal infections might not produce recognizable symptoms until complications (e.g., PID) have occurred. PID can results in tubal scarring that lead to infertility or ectopic pregnancy.

#### **HIV AND AIDS SURVEILLANCE DATA**

HIV case reports represent persons who have a confirmed diagnosis with human immunodeficiency virus (HIV) only. This represents all new diagnosis of HIV in Alabama regardless of the stage of the disease. Most persons are reported with only HIV infection, but some are reported with a concurrent diagnosis of AIDS (acquired immunodeficiency syndrome). HIV Stage 3 (AIDS) case reports represent persons with HIV infection who have progressed to AIDS. HIV infection and AIDS cases are presented in this report by date of diagnosis.

#### SYPHILIS SURVEILLANCE DATA

Syphilis reports are reported by stage of infection which is determined through a combination of laboratory testing, patient examination and interviews. PriJuney and secondary syphilis have specific signs and symptoms associated with them. Early latent syphilis is asymptomatic but can be staged with confirmation that the infection is less than a year old. PriJuney, secondary and early syphilis cases comprise "early syphilis" cases. Alabama conducts interviews on all early syphilis cases.

#### TRICHOMONIASIS SURVEILLANCE DATA

Trichomoniasis case reports represent persons who have a laboratory confirmed case of trichomoniasis infection. It is the most curable sexually transmitted disease. Trichomoniasis is often asymptomatic in females and males. The infection is more common in women than in men, and older women are more likely than younger women to be infected. Untreated trichomoniasis infection can increase the risk of HIV infection in men and women.

#### CENTER FOR DISEASE CONTROL AND PREVENTION TREATMENT GUIDELINES

**Chlamydia:** Azithromycin 1 g PO in a single dose or Doxycycline 100 mg PO twice a day for 7 days **Gonorrhea:** Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1 g PO in a single dose

or Ceftriaxone 250 mg IM in a single dose PLUS Doxycycline 100 mg PO twice a day for 7 days **If Ceftriaxone is not available:** Cefixime 400mg orally in a single dose PLUS Azithromycin 1 g

PO in a single dose

Syphilis: Early Syphilis – Bicillin 2.4 MU IM in a single dose

Late Syphilis - Bicillin 2.4 MU IM weekly for three consecutive weeks

Neuro Syphilis – Aqueous crystalline penicillin G 18-24 MU per day, divided into 3-4 MU IV every

4 hours or continuous infusion for 10-14 days

**Trichomoniasis:** Metronidazole 2 g PO in a single dose or Tinidazole 2 g PO in a single dose

CDC Treatment Guidelines: http://www.cdc.gov/std/tg2016/toc.htm

2016 Chlam	ydia Report	1st Qtr		2 <sup>nd</sup>	Qtr	3 <sup>rd</sup>	Qtr	4 <sup>th</sup> Qtr		Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	1	0.05	0	0.00	N/A	N/A	N/A	N/A	1	0.03
	10-14	4	0.21	3	0.16	N/A	N/A	N/A	N/A	7	0.18
	15-19	371	19.38	435	22.49	N/A	N/A	N/A	N/A	806	20.95
	20-24	805	42.06	787	40.69	N/A	N/A	N/A	N/A	1592	41.37
	25-29	399	20.85	383	19.80	N/A	N/A	N/A	N/A	782	20.32
Mala	30-34	173	9.04	150	7.76	N/A	N/A	N/A	N/A	323	8.39
Male	35-39	73	3.81	88	4.55	N/A	N/A	N/A	N/A	161	4.18
	40-44	35	1.83	44	2.28	N/A	N/A	N/A	N/A	79	2.05
	45-54	39	2.04	30	1.55	N/A	N/A	N/A	N/A	69	1.79
	55-64	12	0.63	7	0.36	N/A	N/A	N/A	N/A	19	0.49
	65+	2	0.10	7	0.36	N/A	N/A	N/A	N/A	9	0.23
	Total	1914	100.00	1934	100.00	N/A	N/A	N/A	N/A	3848	100.00
	0-9	0	0.00	3	0.06	N/A	N/A	N/A	N/A	3	0.03
	10-14	35	0.79	40	0.85	N/A	N/A	N/A	N/A	75	0.82
	15-19	1490	33.57	1553	24.63	N/A	N/A	N/A	N/A	3043	33.36
	20-24	1845	41.56	1868	39.90	N/A	N/A	N/A	N/A	3713	40.71
	25-29	666	15.00	749	16.00	N/A	N/A	N/A	N/A	1415	15.51
Famala	30-34	231	5.20	269	5.75	N/A	N/A	N/A	N/A	500	5.48
Female	35-39	109	2.46	121	2.58	N/A	N/A	N/A	N/A	230	2.52
	40-44	35	0.79	39	0.83	N/A	N/A	N/A	N/A	74	0.81
	45-54	19	0.43	30	0.64	N/A	N/A	N/A	N/A	49	0.54
	55-64	7	0.16	5	0.11	N/A	N/A	N/A	N/A	12	0.13
	65+	2	0.05	5	0.11	N/A	N/A	N/A	N/A	7	0.08
	Total	4439	100.00	4682	100.00	N/A	N/A	N/A	N/A	9121	100.00
	0-9	1	0.02	3	0.05	N/A	N/A	N/A	N/A	4	0.03
	10-14	39	0.61	43	0.65	N/A	N/A	N/A	N/A	82	0.63
	15-19	1882	29.40	1988	30.05	N/A	N/A	N/A	N/A	3870	29.61
	20-24	2671	41.73	2655	40.13	N/A	N/A	N/A	N/A	5326	40.75
	25-29	1069	16.70	1132	17.11	N/A	N/A	N/A	N/A	2201	16.84
	30-34	406	6.34	419	6.33	N/A	N/A	N/A	N/A	825	6.31
Total	35-39	182	2.84	209	3.16	N/A	N/A	N/A	N/A	391	2.99
	40-44	70	1.09	83	1.25	N/A	N/A	N/A	N/A	153	1.17
	45-54	58	0.91	60	0.91	N/A	N/A	N/A	N/A	118	0.90
	55-64	19	0.30	12	0.18	N/A	N/A	N/A	N/A	31	0.24
	65+	4	0.06	12	0.18	N/A	N/A	N/A	N/A	16	0.12
	Total	6401	100.00	6669	100.00	N/A	N/A	N/A	N/A	13070	100.00

2016 Gonor	2016 Gonorrhea Report		Qtr	2 <sup>nd</sup>	Qtr	3 <sup>rd</sup> Qtr		4 <sup>th</sup> Qtr		Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	1	0.11	6	0.58	N/A	N/A	N/A	N/A	7	0.35
	15-19	125	13.37	177	16.99	N/A	N/A	N/A	N/A	302	15.28
	20-24	360	38.50	352	33.78	N/A	N/A	N/A	N/A	712	36.01
	25-29	196	21.00	202	19.39	N/A	N/A	N/A	N/A	398	20.13
	30-34	97	10.37	125	12.00	N/A	N/A	N/A	N/A	222	11.23
Male	35-39	63	6.74	74	7.10	N/A	N/A	N/A	N/A	137	6.93
	40-44	40	4.28	43	4.13	N/A	N/A	N/A	N/A	83	4.20
	45-54	32	3.42	36	3.45	N/A	N/A	N/A	N/A	68	3.44
	55-64	15	1.60	21	2.02	N/A	N/A	N/A	N/A	36	1.82
	65+	6	0.64	6	0.58	N/A	N/A	N/A	N/A	12	0.61
	Total	935	100.00	1042	100.00	N/A	N/A	N/A	N/A	1977	100.00
	0-9	0	0.00	0	0	N/A	N/A	N/A	N/A	0	0.00
	10-14	6	0.67	8	0.85	N/A	N/A	N/A	N/A	14	0.76
	15-19	248	27.90	267	28.25	N/A	N/A	N/A	N/A	515	28.08
	20-24	365	41.05	374	39.58	N/A	N/A	N/A	N/A	739	40.29
	25-29	151	16.99	176	18.62	N/A	N/A	N/A	N/A	327	17.83
Famala.	30-34	59	6.64	61	6.46	N/A	N/A	N/A	N/A	120	6.54
Female	35-39	33	3.71	36	3.81	N/A	N/A	N/A	N/A	69	3.76
	40-44	13	1.46	8	0.85	N/A	N/A	N/A	N/A	21	1.15
	45-54	11	1.24	9	0.95	N/A	N/A	N/A	N/A	20	1.09
	55-64	2	0.22	6	0.64	N/A	N/A	N/A	N/A	8	0.44
	65+	1	0.11	0	0.00	N/A	N/A	N/A	N/A	1	0.05
	Total	889	100.00	945	100.00	N/A	N/A	N/A	N/A	1834	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	7	0.38	14	0.70	N/A	N/A	N/A	N/A	21	0.55
	15-19	380	20.72	444	22.26	N/A	N/A	N/A	N/A	824	21.52
	20-24	728	39.70	726	36.39	N/A	N/A	N/A	N/A	1454	37.97
	25-29	347	18.92	378	18.95	N/A	N/A	N/A	N/A	725	18.93
Takel	30-34	156	8.51	186	9.32	N/A	N/A	N/A	N/A	342	8.93
Total	35-39	96	5.23	110	5.51	N/A	N/A	N/A	N/A	206	5.38
	40-44	53	2.89	51	2.56	N/A	N/A	N/A	N/A	104	2.72
	45-54	43	2.34	45	2.26	N/A	N/A	N/A	N/A	88	2.30
	55-64	17	0.93	27	1.35	N/A	N/A	N/A	N/A	44	1.15
	65+	7	0.38	6	0.30	N/A	N/A	N/A	N/A	13	0.34
	Total	1834	100.00	1995	100.00	N/A	N/A	N/A	N/A	3829	100.00

2016 Trichom	2016 Trichomoniasis Report		1st Qtr		Qtr	3 <sup>rd</sup>	Qtr	4 <sup>th</sup> Qtr		Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	1	0.28	1	0.32	N/A	N/A	N/A	N/A	2	0.30
	15-19	11	3.13	12	3.75	N/A	N/A	N/A	N/A	23	3.43
	20-24	78	22.22	56	17.50	N/A	N/A	N/A	N/A	134	19.97
	25-29	76	21.65	67	20.94	N/A	N/A	N/A	N/A	113	16.84
Mala	30-34	53	15.10	47	14.69	N/A	N/A	N/A	N/A	100	14.90
Male	35-39	37	10.54	43	13.44	N/A	N/A	N/A	N/A	80	11.92
	40-44	26	7.41	29	9.06	N/A	N/A	N/A	N/A	55	8.20
	45-54	30	8.55	33	10.31	N/A	N/A	N/A	N/A	63	9.39
	55-64	30	8.55	20	6.25	N/A	N/A	N/A	N/A	50	7.45
	65+	9	2.56	12	3.75	N/A	N/A	N/A	N/A	21	3.13
	Total	351	100.00	320	100.00	N/A	N/A	N/A	N/A	671	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	9	0.34	5	0.20	N/A	N/A	N/A	N/A	14	0.28
	15-19	237	9.04	217	8.79	N/A	N/A	N/A	N/A	454	8.92
	20-24	732	27.92	679	27.51	N/A	N/A	N/A	N/A	1411	27.72
	25-29	623	23.76	564	22.85	N/A	N/A	N/A	N/A	1187	23.32
	30-34	416	15.87	373	15.11	N/A	N/A	N/A	N/A	789	15.50
Female	35-39	259	9.88	259	10.49	N/A	N/A	N/A	N/A	518	10.18
	40-44	151	5.76	163	6.60	N/A	N/A	N/A	N/A	314	6.17
	45-54	155	5.91	166	6.73	N/A	N/A	N/A	N/A	321	6.31
	55-64	39	1.49	38	1.54	N/A	N/A	N/A	N/A	77	1.51
	65+	1	0.04	4	0.16	N/A	N/A	N/A	N/A	5	0.10
	Total	2622	100.00	2468	100.00	N/A	N/A	N/A	N/A	5090	100.00
	0-9	1	0.03	0	0.00	N/A	N/A	N/A	N/A	1	0.02
	10-14	10	0.34	6	0.21	N/A	N/A	N/A	N/A	16	0.28
	15-19	254	8.51	229	8.20	N/A	N/A	N/A	N/A	483	8.36
	20-24	814	27.27	735	26.31	N/A	N/A	N/A	N/A	1549	30.43
	25-29	699	23.42	631	22.58	N/A	N/A	N/A	N/A	1330	23.01
	30-34	469	15.71	420	15.03	N/A	N/A	N/A	N/A	889	15.38
Total	35-39	296	9.92	302	10.81	N/A	N/A	N/A	N/A	598	10.35
	40-44	177	5.93	192	6.87	N/A	N/A	N/A	N/A	369	6.39
	45-54	185	6.20	199	7.12	N/A	N/A	N/A	N/A	384	6.64
	55-64	70	2.35	58	2.08	N/A	N/A	N/A	N/A	128	2.21
	65+	10	0.34	16	0.57	N/A	N/A	N/A	N/A	26	0.45
	Total	2985	100.00	2794	100.00	N/A	N/A	N/A	N/A	5779	100.00

2016 P&S Sy	2016 P&S Syphilis Report		Qtr	2 <sup>nd</sup>	Qtr	3 <sup>rd</sup>	Qtr	4 <sup>th</sup> Qtr		Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	15-19	3	6.00	5	8.06	N/A	N/A	N/A	N/A	9	8.04
	20-24	16	32.00	12	19.35	N/A	N/A	N/A	N/A	28	25.00
	25-29	15	30.00	19	30.65	N/A	N/A	N/A	N/A	34	30.36
	30-34	7	14.00	8	12.90	N/A	N/A	N/A	N/A	15	13.39
Male	35-39	4	8.00	5	8.06	N/A	N/A	N/A	N/A	9	8.03
	40-44	2	4.00	5	8.06	N/A	N/A	N/A	N/A	7	6.25
	45-54	2	4.00	4	6.45	N/A	N/A	N/A	N/A	5	4.46
	55-64	0	0.00	3	4.84	N/A	N/A	N/A	N/A	3	2.68
	65+	1	2.00	1	1.61	N/A	N/A	N/A	N/A	2	1.79
	Total	50	100.00	62	100.00	N/A	N/A	N/A	N/A	112	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	1	9.09	N/A	N/A	N/A	N/A	1	3.33
	15-19	4	21.05	6	54.55	N/A	N/A	N/A	N/A	10	33.30
	20-24	8	42.11	2	18.18	N/A	N/A	N/A	N/A	10	33.30
	25-29	3	15.79	0	0.00	N/A	N/A	N/A	N/A	3	10.00
Famala	30-34	2	10.53	0	0.00	N/A	N/A	N/A	N/A	2	6.67
Female	35-39	1	5.26	0	0.00	N/A	N/A	N/A	N/A	1	3.33
	40-44	1	5.26	0	0.00	N/A	N/A	N/A	N/A	1	3.33
	45-54	0	0.00	1	9.09	N/A	N/A	N/A	N/A	1	3.33
	55-64	0	0.00	1	9.09	N/A	N/A	N/A	N/A	1	3.33
	65+	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	Total	19	100.00	11	100.00	N/A	N/A	N/A	N/A	30	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	1	1.37	N/A	N/A	N/A	N/A	1	0.70
	15-19	7	10.14	12	16.44	N/A	N/A	N/A	N/A	19	13.38
	20-24	24	34.78	14	19.18	N/A	N/A	N/A	N/A	38	26.76
	25-29	18	26.09	19	26.03	N/A	N/A	N/A	N/A	37	26.06
Tetal	30-34	9	13.04	8	10.96	N/A	N/A	N/A	N/A	17	11.97
Total	35-39	5	7.25	5	6.85	N/A	N/A	N/A	N/A	10	7.04
	40-44	3	4.35	5	6.85	N/A	N/A	N/A	N/A	8	5.63
	45-54	2	2.90	4	5.48	N/A	N/A	N/A	N/A	6	4.22
	55-64	0	0.00	4	5.48	N/A	N/A	N/A	N/A	4	2.82
	65+	1	1.45	1	1.37	N/A	N/A	N/A	N/A	2	1.41
	Total	69	100.00	73	100.00	N/A	N/A	N/A	N/A	142	100.00

2016 Early Laten	2016 Early Latent Syphilis Report		1 <sup>st</sup> Qtr		Qtr	3 <sup>rd</sup> Qtr		4 <sup>th</sup> Qtr		Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	15-19	2	6.25	1	2.78	N/A	N/A	N/A	N/A	3	4.42
	20-24	10	31.25	6	16.67	N/A	N/A	N/A	N/A	16	23.53
	25-29	6	18.75	7	19.44	N/A	N/A	N/A	N/A	13	19.12
	30-34	3	9.38	7	19.44	N/A	N/A	N/A	N/A	10	14.71
Male	35-39	1	3.13	6	16.67	N/A	N/A	N/A	N/A	7	10.29
	40-44	4	12.50	1	2.78	N/A	N/A	N/A	N/A	5	7.35
	45-54	5	15.63	4	11.11	N/A	N/A	N/A	N/A	9	13.23
	55-64	1	3.13	4	11.11	N/A	N/A	N/A	N/A	5	7.35
	65+	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	Total	32	100.00	36	100.00	N/A	N/A	N/A	N/A	68	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	15-19	2	20.00	1	11.11	N/A	N/A	N/A	N/A	3	15.79
	20-24	4	40.00	4	44.44	N/A	N/A	N/A	N/A	8	42.11
	25-29	2	20.00	3	33.33	N/A	N/A	N/A	N/A	5	26.32
	30-34	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
Female	35-39	1	10.00	0	0.00	N/A	N/A	N/A	N/A	1	5.26
	40-44	1	10.00	0	0.00	N/A	N/A	N/A	N/A	1	5.26
	45-54	0	0.00	1	11.11	N/A	N/A	N/A	N/A	1	5.26
	55-64	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	65+	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	Total	10	100.00	9	100.00	N/A	N/A	N/A	N/A	19	100.00
	0-9	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	15-19	4	9.52	2	4.44	N/A	N/A	N/A	N/A	6	6.90
	20-24	14	33.33	10	22.22	N/A	N/A	N/A	N/A	24	27.59
	25-29	8	19.05	10	22.22	N/A	N/A	N/A	N/A	18	20.69
	30-34	3	7.14	7	15.56	N/A	N/A	N/A	N/A	10	11.24
Total	35-39	2	4.76	6	13.33	N/A	N/A	N/A	N/A	8	9.20
	40-44	5	11.09	1	2.22	N/A	N/A	N/A	N/A	6	6.90
	45-54	5	11.09	5	11.11	N/A	N/A	N/A	N/A	10	11.24
	55-64	1	2.38	4	8.89	N/A	N/A	N/A	N/A	5	5.75
	65+	0	0.00	0	0.00	N/A	N/A	N/A	N/A	0	0.00
	Total	42	100.00	45	100.00	N/A	N/A	N/A	N/A	87	100.00

	CHLAMYDIA			G	ONORRHE	Α	TRICHOMONIASIS			
Year to Date	2014 Jan-June	2015 Jan-June	2016 Jan-June	2014 Jan-June	2015 Jan-June	2016 Jan-June	2014 Jan-June	2015 Jan-June	2016 Jan-June	
Autuaga	107	95	117	29	20	12	33	29	28	
Baldwin	311	353	338	76	61	82	40	38	33	
Barbour	97	78	80	33	20	22	70	55	67	
Bibb	48	37	44	12	14	16	27	24	22	
Blount	45	28	47	3	2	16	12	13	7	
Bullock	47	41	46	12	24	9	17	13	24	
Butler	81	101	85	14	26	11	38	53	33	
Calhoun	422	348	364	117	97	107	170	195	184	
Chambers	148	136	122	35	16	41	71	73	73	
Cherokee	40	24	33	6	12	5	20	12	16	
Chilton	72	66	80	22	13	24	33	28	38	
Choctaw	30	26	24	5	8	6	17	12	22	
Clarke	92	86	69	14	8	7	54	62	37	
Clay	29	25	16	6	13	6	12	17	17	
Cleburne	15	21	29	2	2	5	10	7	10	
Coffee	142	132	134	36	39	21	59	61	58	
Colbert	136	130	112	24	28	16	78	75	64	
Conecuh	32	44	34	2	0	4	34	20	26	
Coosa	22	28	19	0	13	6	12	6	18	
Covington	76	95	99	12	6	7	42	50	27	
Crenshaw	42	44	54	6	12	15	27	20	24	
Cullman	121	135	125	8	15	15	29	24	47	
Dale	143	138	151	36	36	38	81	60	88	
Dallas	197	212	253	27	42	46	135	148	133	
DeKalb	82	76	83	18	9	8	19	31	31	
Elmore	194	168	161	46	47	43	63	77	72	
Escambia	103	97	110	30	26	24	46	53	60	
Etowah	337	168	299	102	74	65	151	126	174	
Fayette	39	37	41	0	13	19	22	28	15	
Franklin	52	57	49	5	10	7	28	26	23	
Geneva	65	36	54	24	13	15	43	37	28	
Greene	57	45	51	18	11	9	46	35	33	
Hale	118	73	73	21	16	23	51	46	41	

Year to Date	C	HLAMYDI	A	G	ONORRHE	ΞA	TRICHOMONIASIS			
Henry	39	39	36	11	7	11	36	32	33	
Houston	425	345	325	131	99	92	310	265	214	
Jackson	73	74	56	5	7	10	21	22	27	
Jefferson	2494	2465	2946	805	883	1180	1161	1262	1316	
LaJune	25	28	22	6	8	16	19	8	17	
Lauderdale	180	211	192	22	36	24	112	103	104	
Lawrence	59	49	47	2	7	12	37	40	19	
Lee	371	426	413	77	116	138	136	92	88	
Limestone	134	115	102	35	33	23	73	75	69	
Lowndes	52	71	54	13	9	13	34	18	34	
Macon	131	117	98	35	23	28	49	33	40	
Madison	943	992	1018	321	384	443	222	230	267	
Juneengo	81	71	54	12	17	11	39	37	39	
Juneion	49	37	37	5	6	16	15	28	28	
Juneshall	106	104	122	11	29	20	35	29	27	
Mobile	1525	1446	1528	359	265	274	646	653	571	
Monroe	67	45	37	6	6	6	41	34	24	
Montgomery	1380	1415	1216	528	392	311	500	439	358	
Morgan	213	183	212	39	53	51	122	113	112	
Perry	45	53	43	6	3	12	30	33	31	
Pickens	68	71	64	14	10	14	35	41	24	
Pike	161	147	170	53	34	50	60	78	84	
Randolph	50	54	55	6	6	4	36	33	32	
Russell	227	197	234	54	67	65	96	76	81	
Shelby	189	242	216	44	47	62	60	81	63	
St Clair	99	106	134	27	40	66	56	54	52	
Sumter	74	63	84	12	11	22	41	28	40	
Talladega	274	242	268	98	73	101	146	160	162	
Tallapoosa	99	100	103	13	28	31	80	61	75	
Tuscaloosa	750	638	869	128	138	225	284	263	234	
Walker	151	147	133	40	39	57	63	59	74	
Washington	34	41	34	11	7	9	29	18	14	
Wilcox	54	52	52	6	8	9	39	53	44	
Winston	34	33	23	1	1	2	18	14	19	
Total	14230	13685	13070	3746	3648	3829	6273	6124	5779	

	P&S SYPHILIS		.IS	EARLY	LATENT S'	YPHILIS	OTHER SYPHILIS			
Year to Date	2014 Jan-June	2015 Jan-June	2016 Jan-June	2014 Jan-June	2015 Jan-June	2016 Jan-June	2014 Jan-June	2015 Jan-June	2016 Jan-June	
Autuaga	0	0	1	0	2	0	0	0	1	
Baldwin	3	4	4	1	4	1	1	6	2	
Barbour	1	0	0	0	0	0	1	1	1	
Bibb	0	0	0	2	0	0	0	0	0	
Blount	0	0	0	0	0	0	0	0	0	
Bullock	0	0	0	0	0	3	0	0	1	
Butler	0	1	1	0	0	0	0	0	0	
Calhoun	1	2	0	1	3	0	3	5	1	
Chambers	0	0	1	0	0	3	2	1	1	
Cherokee	0	0	0	0	0	1	0	1	0	
Chilton	0	0	0	0	0	0	0	0	2	
Choctaw	0	0	0	0	0	1	0	0	0	
Clarke	0	1	0	0	0	0	0	0	0	
Clay	0	0	0	0	0	1	0	1	0	
Cleburne	0	0	0	1	0	1	0	0	0	
Coffee	0	1	1	0	0	1	0	0	0	
Colbert	1	2	0	1	3	0	1	0	0	
Conecuh	0	0	0	0	0	0	1	0	0	
Coosa	0	0	0	0	1	0	0	0	1	
Covington	0	0	0	1	0	0	2	0	0	
Crenshaw	0	0	0	0	0	0	0	0	0	
Cullman	0	0	1	0	0	1	0	1	1	
Dale	1	2	0	0	0	1	1	1	0	
Dallas	0	5	1	0	2	1	0	1	0	
DeKalb	0	0	2	0	1	0	0	1	0	
Elmore	0	0	5	1	0	3	2	0	0	
Escambia	1	0	1	1	0	0	1	2	0	
Etowah	3	1	3	2	1	2	2	3	1	
Fayette	0	0	0	1	0	0	0	0	0	
Franklin	0	0	0	0	0	0	0	1	0	
Geneva	1	0	0	0	0	0	0	2	0	
Greene	1	0	0	0	0	0	1	0	0	
Hale	0	0	0	0	0	0	1	0	0	

Year to Date	P8	S SYPHIL	.IS	EARLY	LATENT S'	YPHILIS	OTHER SYPHILIS			
Henry	0	0	0	0	0	0	0	0	1	
Houston	3	2	6	3	0	0	6	6	6	
Jackson	0	1	0	0	0	0	1	0	0	
Jefferson	15	35	37	15	25	24	31	33	15	
LaJune	0	0	0	0	0	0	0	0	0	
Lauderdale	1	1	2	0	0	2	1	0	0	
Lawrence	0	1	0	0	0	2	0	0	0	
Lee	0	6	3	0	0	5	1	2	1	
Limestone	0	0	1	0	0	0	1	1	1	
Lowndes	0	0	0	0	0	0	0	1	0	
Macon	0	0	1	0	0	1	0	0	0	
Madison	8	18	23	5	15	12	13	4	2	
Juneengo	1	0	0	0	0	0	0	0	3	
Juneion	0	0	0	0	0	0	0	0	0	
Juneshall	1	0	0	1	0	1	0	0	1	
Mobile	4	11	16	7	1	7	17	14	10	
Monroe	0	0	0	1	0	0	0	0	0	
Montgomery	12	26	22	8	14	14	9	12	5	
Morgan	3	0	2	0	0	1	0	1	1	
Perry	0	0	0	0	0	0	0	0	0	
Pickens	0	0	0	0	0	0	1	1	0	
Pike	0	2	1	0	0	0	0	1	0	
Randolph	0	0	0	1	0	0	0	0	0	
Russell	1	3	4	5	1	4	1	0	1	
Shelby	3	0	1	6	3	6	1	0	3	
St Clair	1	0	0	0	0	0	4	2	1	
Sumter	1	3	0	0	0	0	0	0	0	
Talladega	1	1	3	1	2	0	3	3	0	
Tallapoosa	0	0	0	2	7	0	0	1	0	
Tuscaloosa	2	9	9	4	6	0	2	3	2	
Walker	0	1	0	0	2	1	0	0	0	
Washington	0	0	0	0	0	0	0	0	0	
Wilcox	0	0	0	0	0	0	0	2	1	
Winston	0	0	1	1	1	0	1	0	0	
Total	71	139	142	72	94	87	114	118	66	

	HI	V, NON AII	os	HIV, STAGE 3 (AIDS)				
Year to Date	2014 Jan-June	2015 Jan-June	2016 Jan-June	2014 Jan-June	2015 Jan-June	2016 Jan-June		
Autuaga	_	_	_	_	0	0		
Baldwin	5	8	_	_	_	_		
Barbour	_	_	0	_	_	0		
Bibb	0	_	0	0	0	0		
Blount	_	0	_	0	0	0		
Bullock	8	_	0	_	0	0		
Butler	_	0	0	0	0	0		
Calhoun	_	_	_	_	0	_		
Chambers	_	_	_	0	_	0		
Cherokee	_	0	0	0	0	0		
Chilton	0	-	_	0	0	0		
Choctaw	0	0	_	0	0	0		
Clarke	0	0	_	0	0	0		
Clay	0	_	_	0	_	0		
Cleburne	0	0	0	0	_	0		
Coffee	_	_	_	0	0	0		
Colbert	_	_	_	_	0	0		
Conecuh	0	_	_	_	0	0		
Coosa	_	_	_	-	0	0		
Covington	0	-	0	0	0	0		
Crenshaw	_	-	_	_	0	0		
Cullman	_	-	0	0	0	0		
Dale	14	6	-	-	_	0		
Dallas	_	-	-	-	-	0		
DeKalb	_	_	0	_	0	0		
Elmore	_	_	0	0		0		
Escambia	0	_	0	0	0	0		
Etowah		_	_	0		0		
Fayette	0	0	0	0	0	0		
Franklin	0	0	0	0	0	-		
Geneva	_	0	0	0	0	0		
Greene	_	0	0	0	0	0		
Hale		0	0	_	-	0		

Year to Date	Н	V, NON AII	DS .	HIV, STAGE 3 (AIDS)				
Henry	0	_	_	0	0	0		
Houston	_	_	6	-	0	-		
Jackson	0	0	0	0	0	0		
Jefferson	63	25	29	19	6	_		
LaJune	_	0	_	0	0	0		
Lauderdale	_	0	_	_	_	_		
Lawrence	_	0	0	0	0	0		
Lee	_	9	5	0	_	_		
Limestone	_	_	0	_	_	0		
Lowndes	0	0	0	0	0	_		
Macon	0	0	-	0	0	0		
Madison	19	_	_	5	0	0		
Juneengo	0	0	0	0	0	_		
Juneion	0	0	0	0	0	0		
Juneshall	_	_	0	0	0	0		
Mobile	52	31	38	9	6	8		
Monroe	0	_	0	0	_	0		
Montgomery	40	47	33	11	11	7		
Morgan	_	0	_	_	0	_		
Perry	0	_	0	0	0	0		
Pickens	_	0	0	_	0	0		
Pike	0	_	_	_	_	0		
Randolph	0	0	_	0	0	0		
Russell	7	_	7	_	_	_		
Shelby	6	_	_	0	0	0		
St Clair	-	5	0	0	-	0		
Sumter	-	_	0	0	0	0		
Talladega	0	_	_	_	_	_		
Tallapoosa	0	0	-	_	0	0		
Tuscaloosa	7	9	_	_	_	0		
Walker	-	-	0	_	-	0		
Washington	0	0	-	0	0	0		
Wilcox	0	-	-	0	0	_		
Winston	0	0	0	0	0	0		
Total	285	200	168	75	53	32		

Note: 2016 cases should be interpreted with extreme caution as not all reported cases have been entered into the HIV Surveillance database. Newly diagnosed HIV, non-AIDS includes newly diagnosed HIV infections not progressing to stage 3 (AIDS) within 30 days of diagnosis. Newly diagnosed HIV, stage 3 (AIDS) includes new and preexisting infections meeting criteria for stage 3 (AIDS) infection. Data accessed July 5, 2016.



# HELP PREVENT CONGENITAL SYPHILIS



Test at first prenatal visit



Assess sexual risk behavior during pregnancy



Retesting in third trimester (28-32 weeks gestation) and again at delivery




Treat pregnant females at least 30 days before delivery in accordance with CDC treatment guidelines

If you have any questions, contact the Alabama Department of Public Health, Division of Sexually Transmitted Disease at (334) 206-5350.

Note: Adequate treatment is defined as completion of a penicillin-based regimen, in accordance with CDC treatment guidelines, appropriate for stage of infection, initiated 30 or more days before delivery.

For pregnant women who have history of syphilis or tested positive for syphilis during pregnancy, follow up serologic titer must be monitored closely during the third trimester and repeat treatment 30 days or more before delivery.

# STD PROGRAM MANAGERS BY HEALTH AREA



#### PHA 1

Rhonda Guthmiller 256-383-1231 Colbert CHD

#### PHA 2

Dana Battle 256-533-8687 Madison CHD

#### PHA 3

Deborah Bivins 205-562-6974 Tuscaloosa CHD

#### PHA 4

Lori McManus 205-930-1383 Jefferson CHD

#### PHA 5

Wanda McCrimon 205-685-4166 Shelby CHD

#### PHA 6

Kerry Owens 256-463-2296 ext 1 Cleburne CHD

#### PHA 7

Paul Piepho 251-580-5328 Baldwin CHD

#### PHA 8

Sterling Wimbish 334-293-6421 Montgomery CHD

#### PHA 9

Paul Piepho 251-580-5328 Baldwin CHD

#### **PHA 10**

Sterling Wimbish 334-678-5950 Houston CHD

#### **PHA 11**

Vacant 251-690-8831 Mobile CHD

